Lilly licenses Hanmi’s GLP-2 biologic sonefpeglutide for $1.2bn

gastrointestinal concept magnifying glass

Source:

Agreement to develop and commercialise long-acting GLP drug candidate by South Korea-based biopharma company.

Lilly is adding another medicine to its growing GLP portfolio by licensing a novel long-acting glucagon-like peptide 2 (GLP-2) biologic from Hanmi Pharm, for up to $1.26 billion.

While Hanmi Pharm’s sonefpeglutide (LAPSGLP-2 analog) is being evaluated in an ongoing phase II trial in short bowel syndrome (SBS), Lilly’s current GLP roster for obesity and diabetes includes blockbuster drugs

Already a member? Sign-in

Unlock

Driving innovation in pharma manufacturing

European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.

Become a member to continue reading

By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:

  • Unlimited access to industry intelligence that can make a difference to your business
  • A weekly newsletter keeping the most vital information at the front of your thinking
  • Exclusive invitations to powerful webinars and events featuring high profile experts
  • Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation

Become a member